Posters

Topo-guided refractive cross-linking for keratoconus

Poster Details

First Author: R. Fasciani ITALY

Co Author(s):    C. Radini   A. Caristia   A. Agresta   S. Ambrogio   A. Caporossi        

Abstract Details

Purpose:

through the study of the shape of keratoconus and modulation of the dose of UVA irradiation, it is possible to develop algorithms for treatment or 'Computer modeling' that are intended to reshape and normalize as possible the shape of the cornea.

Setting:

Istitute of Ophthalmology, Catholic University of Sacro Cuore in Rome. Local Ethic Commitee approvved on September 2014.

Methods:

19 patients with keratoconus in II-III Amsler stage, underwent to Corneal Refractive Cross Linking procedure using a KXL II UVA emitting System (30-45 mW /cm2, 1 minutes on / 1 minutes off pulsed accelerated irradiation, dose distributed from 5.4J to 15J) and 0.1% riboflavin solution (Vibex Rapid, Avedro Inc., Waltham, MA, USA). The treatment algorithm has been developed through the determination and processing of the center of mass of the cone by studying the maximum keratometries with Scheimplflug camera (Pentacam, Oculus Inc., Arlington, USA).

Results:

There were no intraoperative and postoperative complications,The mean follow-up of 18 months has put highlights in an average reduction of K max equal to -2.9D and a reduction in the mean refractive cylinder of about -2.42D. No evolution of keratoconus in all treated patients was evident during the follow up. Topographic analysis seems to confirm the reshaping of the keratoconic cornea, with flattening the most curved areas and elevating the most flattened areas, in order to give greater uniformity of corneal shape. Patients who seems benefit most from KXLII, are those with lower UCVA/BCVA and higher Sim K and Refractive Cylinder.

Conclusions:

the topo-guided refractive corneal Cross Linking procedure appears a promising technique for reducing the refractive errors in patients with keratoconus. A long-term follow-up results will be needed to evaluate the efficacy and safety of the technique in the prevention of the evolution of the disease

Financial Disclosure:

NONE